recommendations of 5-ASA use. Th e truth is many patients decide to stop their drugs when feeling well even if it is recommended to remain on 5-ASA to prevent relapse. Second, in this study we were measuring cumulative use so " user " patients did not have to consistently remain on the drug and many patients may wax and wane in their use. Th ird, the percentage use of 38, 13, and 6 % at 1 year, 5 years, and 7.5 years cumulatively refl ect use in Crohn ' s disease and ulcerative colitis combined. 5-ASA is not widely prescribed in Crohn ' s disease in Manitoba and its effi cacy in Crohn ' s disease is minimal at best.
We do agree with the correspondents though that among the numerous studies addressing the issue of 5-ASA and CRC chemoprophylaxis, that none (sic) " have conclusively shown any impact of 5-ASAs on the risk of developing CRC " . While our study may not be the defi nitive or fi nal study on the issue, we hope that it adds suffi cient weight to the body of research in this area that others share the views of ours and the correspondents that to date there is no conclusive evidence of 5-ASA preventing CRC. Rather than other authors writing about this topic as an accepted fact, we would hope they would accept that the concept of 5-ASA preventing CRC in IBD remains unproven. To the Editor: Confocal endomicroscopy is emerging as a safe, minimally invasive means of improving the accuracy of endoscopic screening and surveillance for Barrett ' s esophagus ( 1 ) and colorectal cancer ( 2 ) . When used alongside " redfl ag " techniques such as autofl uorescence imaging or narrow-band imaging (NBI), endomicroscopy enables the gastroenterologist to evaluate the gastric or colonic mucosa with cellular level resolution in a real-time " optical biopsy " ( 3 ). Both endoscope-based and probe-based platforms have demonstrated improved diagnostic yield and very high preliminary accuracy compared with standard endoscopy in prospective, double-blind studies ( 4, 5 ) . However, the cost and learning curve associated with these systems limits their usage to a selected number of academic centers ( 3 ). To enable widespread translation of this promising technology, we developed a high-resolution microendoscope (HRME) in prototype form for under $ 5,000 ( 6, 7 ) . Th e instrument uses a 1-mm diameter probe, which passes through the working channel of a standard gastroscope or colonoscope; images are displayed at 15 frames-per-second at × 400 magnifi cation. A light-emitting diode provides illumination at 445 nm, which is delivered through the probe to the tissue surface. Th e spatial resolution of the probe is 4.4 μ m and the fi eld-of-view is 720 μ m in diameter. In this Letter, we present the fi rst in vivo clinical applications of this technology in the upper and lower gastrointestinal tracts. We present a case involving surveillance and guided therapy of Barrett ' s esophagus, followed by three cases illustrating the characteristic features of normal, infl ammatory, and adenomatous tissue in the colon. Th is study was approved by the Institutional Review Boards of Mount Sinai Hospital and Rice University. Similar to several confocal endomicroscopy studies ( 3 ), the HRME uses fl uorescent contrast agents, typically either topical acrifl avine or profl avine. In the esophagus, this enables the discrete, evenly spaced nuclei of normal squamous mucosa to be distinguished from the glandular appearance of columnar metaplasia ( Figure 1a -d ) . Barrett ' s metaplasia has previously been characterized on HRME by large glands with intact nuclear polarity, whereas high-grade dysplasia (HGD) exhibits crowded, irregular glands, and loss of nuclear polarity ( 6, 8 ) .
Low-Cost
A 47-year-old male with longstanding refl ux symptoms and Barrett ' s esophagus was referred for endoscopic evaluation. Th e patient underwent high-defi nition whitelight endoscopy ( Figure 1e ) with NBI ( Figure 1f ), which revealed a 6-cm segment of Barrett ' s (Prague Classifi cation C5M6) with several " NBI-abnormal " areas showing a distorted mucosal and vascular pattern. Th ese areas were sprayed with 1 -2 ml of 0.01 % (w / v) profl avine and imaged with the HRME probe (see Supplementary Video S1 online). HRME imaging revealed non-neoplastic epithelium in the majority of NBI-abnormal areas. However, focal HGD was noted in two separate areas in the proximal portion of the segment, evidenced by a proliferation of small irregular glandular structures (arrows in Figure 1c and d ) . Th e patient opted for and subsequently underwent endoscopic cryoablation of the Barrett ' s segment ( Figure 1g and h ) .
We have also used the HRME during screening colonoscopy, where the ability to rapidly stratify benign polyps and precancerous adenomas is essential. In normal colonic mucosa, small uniformly spaced circular crypts, absent of glandular distortion or atrophy are readily apparent under HRME imaging ( Figure 2a ) , and also seen in the corresponding histopathology ( Figure 2b ). Small, basally oriented nuclei are also apparent under HRME imaging. With infl ammatory polyps, a dense popula tion of infl ammatory cells is commonly observed on HRME ( Figure 2c ), with only a few irregularly shaped and variably sized glands visible. Tubular adenomas ( Figure 2e ) are easily distinguished; glands appear as irregular structures with heterogeneous orientation, involving elongated, crowded cells, and enlarged nuclei.
Endomicroscopy has the potential to become an important clinical tool ( 9 ), but its overall impact on patient care may ultimately be limited by cost. HRME imaging provides real-time " optical biopsies " with many of the same diagnostically relevant features established for confocal endomicro scopy, yet costs signifi cantly less than probe-and endoscope-based confocal platforms. Low-cost endomicroscopy may prove to be a more widely accessible adjunct to standard endoscopy for managing conditions, including Barrett ' s metaplasia and screening colonoscopy, by assisting the endoscopist in selecting sites for biopsy and / or guiding treatment.
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